HELP Share Price Performance
US$7.25
-0.78 (-9.71%)
6.9% undervalued intrinsic discount
US$7.78
Fair Value
Price US$7.25
AnalystLowTarget US$7.78
AnalystHighTarget US$70.05
BrightSide
Fair ValueUS$7.78
Share Pricen/a
Seeking Alpha • Jul 12
Cybin Inc. Stock Price
- 4 Narratives written by author
- 1 Comments on narratives written by author
- 68 Fair Values set on narratives written by author
HELP Community Narratives
AN
Fair Value
·Fair Value US$7.78 6.9% undervalued intrinsic discount
Psychedelic Therapy Trials Will Face Cash Strain Yet Could Unlock Long Term Upside
0users have liked this narrative
0users have commented on this narrative
4users have followed this narrative
AN
Fair Value
·Fair Value US$70.05 89.7% undervalued intrinsic discount
Late Stage Psychedelic Therapies And Clinic Partnerships Will Reshape Treatment For Depression And Anxiety
1users have liked this narrative
0users have commented on this narrative
2users have followed this narrative
BR
Fair Value
·Fair Value US$0 n/aintrinsic discount
Cybin will leverage its 70 patents for breakthroughs in holistic depression treatment
2users have liked this narrative
1users have commented on this narrative
8users have followed this narrative
Cybin will leverage its 70 patents for breakthroughs in holistic depression treatment
1. Cybin's Intellectual Property : Cybin has over 70 granted patents and 220 patent applications pending across multiple patent families.Read more
BR
US$0
n/aintrinsic discount
Fair Value
Profit Margin
14.75%
Future PE
22.08x
Price in 2030
US$0
Late Stage Psychedelic Therapies And Clinic Partnerships Will Reshape Treatment For Depression And Anxiety
Cybin is trying to bring psychedelic-style treatments for depression and anxiety into clinics in a way that fits today’s mental-health workflows, which could speed up real-world use if the late-stage trials deliver. The big question is whether the studies succeed and whether insurers and clinics adopt the model fast enough to turn scientific progress into a sustainable business.Read more
AN
US$70.05
89.7% undervalued intrinsic discount
Fair Value
Profit Margin
11.79%
Future PE
96.37x
Price in 2029
US$0
Psychedelic Therapy Trials Will Face Cash Strain Yet Could Unlock Long Term Upside
Cybin is racing to bring psychedelic-based treatments for depression and anxiety through late-stage trials, but it may need to raise more money before it ever sells a product. If the studies run smoothly and clinics and insurers embrace short, streamlined treatment sessions, the payoff could be meaningful—but a delay, weaker results, or slow adoption could quickly change the story.Read more
AN
US$7.78
6.9% undervalued intrinsic discount
Fair Value
Profit Margin
19.65%
Future PE
534.11x
Price in 2029
US$0
Interventional Psychiatry And Clinic Partnerships Will Support Long Term Psychedelic Treatment Adoption
Catalysts About Cybin Cybin is a clinical stage company developing psychedelic based treatments for major depressive disorder and generalized anxiety disorder. What are the underlying business or industry changes driving this perspective?Read more
AN
US$49.46
85.3% undervalued intrinsic discount
Fair Value
Profit Margin
21.47%
Future PE
98.85x
Price in 2029
US$0
Trending Discussion
No trending discussion available.
Recently Updated Narratives
BR
Cybin will leverage its 70 patents for breakthroughs in holistic depression treatment
Fair Value: US$0 0% overvalued intrinsic discount
8 fair values setusers have set this as their fair value
1 commentusers have commented on this narrative
0 likesusers have liked this narrative
AN
HELP: Sector Depression Trial Milestones Will Shape This Psychedelic Undervaluation View
Fair Value: US$70.05 89.7% undervalued intrinsic discount
2 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
HELP: Policy Momentum On PTSD Treatments Will Drive Future Psychedelic Therapy Demand
Fair Value: US$7.78 6.9% undervalued intrinsic discount
4 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Cybin Inc. Key Details
About HELP
- Founded
- n/a
- Employees
- 100
- CEO
- WebsiteView website
Cybin Inc., doing business as Helus Pharma, a clinical stage pharmaceutical company, focuses on developing therapies to treat various psychiatric and neurological conditions.It develops HLP003, a deuterated psilocybin analog, which is in phase 3 clinical trial to treat major depressive disorder (MDD); and HLP004, a deuterated N, N-dimethyltryptamine (DMT), which is in phase 2 clinical trial for treating generalized anxiety disorders. The company’ preclinical product includes HLP005, a phenethylamine and tryptamine derivative to treat central nervous system. It has a strategic partnership agreement with Segal Trials to evaluating HLP003 for the adjunctive treatment of major depressive disorder; and with Osmind for mental health treatments. The company is headquartered in Toronto, Canada.
